Holen Sie sich die Stockscreener-App
5.35
1.13%
0.06
Schlusskurs vom Vortag:
$5.29
Offen:
$5.33
24-Stunden-Volumen:
4,451
Relative Volume:
0.05
Marktkapitalisierung:
$460.45M
Einnahmen:
$196.47M
Nettoeinkommen (Verlust:
$-132.90M
KGV:
-3.4372
EPS:
-1.5565
Netto-Cashflow:
$-97.72M
1W Leistung:
+0.38%
1M Leistung:
-10.23%
6M Leistung:
-39.89%
1J Leistung:
-17.41%
1-Tages-Spanne:
$5.28
$5.33
1-Wochen-Bereich:
$5.06
$5.50
52-Wochen-Spanne:
$5.06
$12.25
Valneva Se Adr Stock (VALN) Company Profile
Compare VALN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
5.30 | 459.58M | 196.47M | -132.90M | -97.72M | -1.5565 |
VRTX
Vertex Pharmaceuticals Inc
|
428.25 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.03 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.18 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.00 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Herabstufung | Goldman | Neutral → Sell |
| 2025-08-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-08-03 | Eingeleitet | H.C. Wainwright | Buy |
Valneva Se Adr Aktie (VALN) Neueste Nachrichten
Valneva’s €84M Cash Injection Comes With a Bitter Pill for Shareholders - AD HOC NEWS
VLA.PA Technical Analysis | Trend, Signals & Chart Patterns | VALNEVA SE (EPA:VLA) - ChartMill
VLA.PA Stock Price, Quote & Chart | VALNEVA SE (EPA:VLA) - ChartMill
Valneva shares slide after US pullback on chikungunya vaccine filing - MSN
Valneva (NASDAQ:VALN) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Valneva SE Sponsored ADR (NASDAQ:VALN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Goldman Sachs downgrades Valneva stock rating to sell on Lyme vaccine uncertainty - Investing.com
Valneva (NASDAQ:VALN) Shares Gap UpTime to Buy? - MarketBeat
Valneva's Dual Challenge: Legal Scrutiny Meets Commercial Reality - AD HOC NEWS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - PR Newswire
Guggenheim cuts Valneva stock price target to $11 on Lyme vaccine - Investing.com
Valneva SE Under Investigation for Securities Fraud - Intellectia AI
VALN stock nosedives on mixed results from Lyme disease vaccine study - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Valneva (NASDAQ:VALN) Shares Gap DownHere's Why - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Valneva Faces Mounting Legal Pressure Following Clinical Trial Setback - AD HOC NEWS
2026-04-06 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation | NDAQ:VALN | Press Release - Stockhouse
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Valneva's Travel Vaccines: Strategic Pivot to Emerging Markets Drives Long-Term Investor Value in Bi - AD HOC NEWS
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Declaration of shares and voting rights of Valneva SE – March 2026 - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Valneva (NASDAQ:VALN) Sees Large Volume IncreaseHere's Why - MarketBeat
Short Interest in Valneva SE Sponsored ADR (NASDAQ:VALN) Rises By 25.4% - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect - ACCESS Newswire
2026-03-27 | Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:VALN | Press Release - Stockhouse
Valneva, Venture Global And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN - FinancialContent
VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study - Yahoo Finance
VALN Shares Plunge Following Uncertain Outcomes in Lyme Disease Vaccine Trial - Bitget
Jefferies reiterates Valneva stock Buy rating after Lyme trial data - Investing.com
Pfizer, Valneva Lyme disease vaccine shows 73% efficacy in trial - Investing.com
HC Wainwright Has Positive Forecast for Valneva Q3 Earnings - MarketBeat
Valneva (NASDAQ:VALN) Shares Gap Down – Here’s Why - Defense World
FY2030 Earnings Forecast for Valneva Issued By HC Wainwright - Defense World
FY2030 Earnings Estimate for Valneva Issued By HC Wainwright - MarketBeat
Finanzdaten der Valneva Se Adr-Aktie (VALN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):